These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 32964074)
1. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions. Farghaly H; Alshareef M; Alqarni A; Sayed M; Nasr H Eur J Radiol Open; 2020; 7():100268. PubMed ID: 32964074 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of malignant thyroid lesions on [ Nasr H; Farghaly H; Alqarni A; Al-Salem S; Sayed M Eur J Radiol Open; 2021; 8():100373. PubMed ID: 34458507 [TBL] [Abstract][Full Text] [Related]
3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Basu S; Mavi A; Cermik T; Houseni M; Alavi A Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713 [TBL] [Abstract][Full Text] [Related]
6. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work? Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314 [TBL] [Abstract][Full Text] [Related]
7. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses. Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243 [TBL] [Abstract][Full Text] [Related]
8. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease. Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026 [TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
10. Dual-time point Parghane RV; Basu S Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277 [TBL] [Abstract][Full Text] [Related]
11. Dual time point Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675 [TBL] [Abstract][Full Text] [Related]
12. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue. Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304 [TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Dual Time Point Einama T; Yamagishi Y; Takihata Y; Konno F; Kobayashi K; Yonamine N; Fujinuma I; Tsunenari T; Kouzu K; Nakazawa A; Iwasaki T; Shinto E; Ishida J; Ueno H; Kishi Y Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954351 [TBL] [Abstract][Full Text] [Related]
14. The clinical value of texture analysis of dual-time-point Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic ability of [ Lee DY; Kim YI; Ryu JS Eur Radiol; 2025 Jan; 35(1):479-486. PubMed ID: 39026061 [TBL] [Abstract][Full Text] [Related]
16. The Clinical Role of Dual-Time-Point (18)F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma. Lee S; Park T; Park S; Pahk K; Rhee S; Cho J; Jeong E; Kim S; Choe JG Nucl Med Mol Imaging; 2014 Jun; 48(2):121-9. PubMed ID: 24900152 [TBL] [Abstract][Full Text] [Related]
17. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions. Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097 [TBL] [Abstract][Full Text] [Related]
18. Role of Ma G; Zhang X; Wang M; Xu X; Xu B; Guan Z Quant Imaging Med Surg; 2021 May; 11(5):2013-2018. PubMed ID: 33936982 [TBL] [Abstract][Full Text] [Related]
19. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046 [TBL] [Abstract][Full Text] [Related]
20. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Suga K; Kawakami Y; Hiyama A; Matsunaga N Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]